Biotek-snakken — Oktober 2024
-
-
Gilead Sciences : Phase 3 Data Shows 96% Reduction In HIV Infections With Lenacapavir https://proinvestor.com/investornyt/1224040/gilead-sciences-phase-3-data-shows-96-reduction-in-hiv-infections-with-lenacapavir
-
Indivior Announces FDA Grants Priority Review For SUBLOCADE Prior Approval Supplement https://proinvestor.com/investornyt/1224036/indivior-announces-fda-grants-priority-review-for-sublocade-prior-approval-supplement
-
Vincerx Reports Positive Initial Clinical Data From VIP943 Phase 1 Dose-Escalation Study https://proinvestor.com/investornyt/1224048/vincerx-reports-positive-initial-clinical-data-from-vip943-phase-1-dose-escalation-study
-
FDA Approves Genentech's Itovebi For Advanced Breast Cancer With PIK3CA Mutation https://proinvestor.com/investornyt/1225691/fda-approves-genentechs-itovebi-for-advanced-breast-cancer-with-pik3ca-mutation
-
FDA Approves Pfizer's HYMPAVZI For Hemophilia A And B Treatment In Adults And Adolescents https://proinvestor.com/investornyt/1226235/fda-approves-pfizers-hympavzi-for-hemophilia-a-and-b-treatment-in-adults-and-adolescents
-
https://saniona.com/newsroom/single-press-release/?slug=saniona-ion-channel-research-collaboration-with-boehringer-ingelheim-reaches-milestone
Saniona Ion Channel Research Collaboration with Boehringer Ingelheim Reaches Milestone
October 14, 2024 at 8:00:00 AM
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind